Alexza Completes Target Enrollment In AZ-104 Phase 2a Clinical Trial In Migraine Patients

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced that it has completed its target patient enrollment in its Phase 2a proof-of-concept clinical trial with AZ-104 (Staccato(R) loxapine) in patients with migraine headache. AZ-104 is a lower dose version of AZ-004, which is being developed to treat acute agitation in patients with schizophrenia or bipolar disorder. [click link for full article]

More: continued here

Filed under: Clinical Trials on December 20th, 2007